The Use of Biologics During the COVID-19 Pandemic

Dupilumab and COVID ‐19: What should we expect?

(2020) Cataldo Patruno et al.   Dermatologic Therapy

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

(2020) April W. Armstrong et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab

(2020) Ulrike Förster-Ruhrmann et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations

(2020) Alecia Blaszczak et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment

(2020) Paolo Gisondi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

(2020) Marilyn T. Wan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

SARS‐CoV‐2 asymptomatic infection in a patient under treatment with dupilumab

(2020) Francesca Caroppo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports

(2020) S. Ferrucci et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York

(2020) Rebecca Haberman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis

(2020) Shintaro Akiyama et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak

(2020) Jesse Veenstra et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic

(2020) Donovan G. Kearns et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

(2020) Satveer K. Mahil et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic

(2020) Maha N. Syed et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

(2020) Joel M. Gelfand et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE